STUDIO RETROSPETTIVO SULL'EFFICACIA DELL'APROTININA NELLA CHIRURGIA VALVOLARE DELL'ADULTO

Translated title of the contribution: Retrospective study on the efficacy of aprotinin in valvular surgery in the adult

P. Gerometta, C. Antona, A. Parolari, P. Fratto, F. Alamanni, R. Spirito, V. Arena, P. Biglioli

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aprotinin effects on postoperative bleeding, redo operations due to excessive bleeding and postoperative blood products use have been retrospectively evaluated on a population of 894 consecutive patients operated upon between 1987 and 1991 for valvular surgery. In this period, aprotinin has been routinely used following the 'High Dose' protocol starting from January 1990. To analyse results, all the patients considered (Group I) were divided into subgroups, following the heart valve operated upon, in 'mitral' patients (391 patients, 43.7%, Group II), 'aortic' patients (375 patients, 41,9%, Group III) and 'mitro-aortic' patients (128 patients, 14.3%, Group IV). Each of these Groups has been subsequently split depending on whether or not they received aprotinin (Subgroups IA, IIA, IIIA, IVA with aprotinin, subgroups IB, IIB, IIIB, IVB without aprotinin). Considering the whole population (Group I), aprotinin determined a significant reduction of post-operative bleeding (499 ± 634 ml Group IA versus 713 ± 572 Group IB, p = 0.000), redo operations for bleeding (15/410, 3.7% Group IA versus 45/484, 9.3% Group IB, p = 0.0000) and consequently the percentage of patients exposed to blood products transfusion (37/410, 9% Group IA versus 163/484, 54.3% Group IB p = 0.0000). When the other Groups (II, III and IV) were considered, aprotinin determined a significant reduction of postoperative bleeding and of donor blood transfusions, while redo operations for bleeding, although less in total number, were not significantly reduced. Moreover, aprotinin has been effective in reducing postoperative blood losses, redo-operation for bleeding and blood use independently of the kind of oxygenator used: bubble vs hollow fibers. We consider that intraoperative administration of aprotinin, following the 'High Dose' protocol, is an important tool in adult valvular surgery to substantially reduce risks related to bleeding, reexplorations and donor blood transfusions.

Original languageItalian
Pages (from-to)47-54
Number of pages8
JournalMinerva Cardioangiologica
Volume43
Issue number1-2
Publication statusPublished - 1995

Fingerprint

Aprotinin
Retrospective Studies
Hemorrhage
Blood Transfusion
Tissue Donors
Oxygenators
Postoperative Hemorrhage
Heart Valves
Population Groups

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

STUDIO RETROSPETTIVO SULL'EFFICACIA DELL'APROTININA NELLA CHIRURGIA VALVOLARE DELL'ADULTO. / Gerometta, P.; Antona, C.; Parolari, A.; Fratto, P.; Alamanni, F.; Spirito, R.; Arena, V.; Biglioli, P.

In: Minerva Cardioangiologica, Vol. 43, No. 1-2, 1995, p. 47-54.

Research output: Contribution to journalArticle

Gerometta, P. ; Antona, C. ; Parolari, A. ; Fratto, P. ; Alamanni, F. ; Spirito, R. ; Arena, V. ; Biglioli, P. / STUDIO RETROSPETTIVO SULL'EFFICACIA DELL'APROTININA NELLA CHIRURGIA VALVOLARE DELL'ADULTO. In: Minerva Cardioangiologica. 1995 ; Vol. 43, No. 1-2. pp. 47-54.
@article{0315acc353774933b5088c5b6ee360b5,
title = "STUDIO RETROSPETTIVO SULL'EFFICACIA DELL'APROTININA NELLA CHIRURGIA VALVOLARE DELL'ADULTO",
abstract = "Aprotinin effects on postoperative bleeding, redo operations due to excessive bleeding and postoperative blood products use have been retrospectively evaluated on a population of 894 consecutive patients operated upon between 1987 and 1991 for valvular surgery. In this period, aprotinin has been routinely used following the 'High Dose' protocol starting from January 1990. To analyse results, all the patients considered (Group I) were divided into subgroups, following the heart valve operated upon, in 'mitral' patients (391 patients, 43.7{\%}, Group II), 'aortic' patients (375 patients, 41,9{\%}, Group III) and 'mitro-aortic' patients (128 patients, 14.3{\%}, Group IV). Each of these Groups has been subsequently split depending on whether or not they received aprotinin (Subgroups IA, IIA, IIIA, IVA with aprotinin, subgroups IB, IIB, IIIB, IVB without aprotinin). Considering the whole population (Group I), aprotinin determined a significant reduction of post-operative bleeding (499 ± 634 ml Group IA versus 713 ± 572 Group IB, p = 0.000), redo operations for bleeding (15/410, 3.7{\%} Group IA versus 45/484, 9.3{\%} Group IB, p = 0.0000) and consequently the percentage of patients exposed to blood products transfusion (37/410, 9{\%} Group IA versus 163/484, 54.3{\%} Group IB p = 0.0000). When the other Groups (II, III and IV) were considered, aprotinin determined a significant reduction of postoperative bleeding and of donor blood transfusions, while redo operations for bleeding, although less in total number, were not significantly reduced. Moreover, aprotinin has been effective in reducing postoperative blood losses, redo-operation for bleeding and blood use independently of the kind of oxygenator used: bubble vs hollow fibers. We consider that intraoperative administration of aprotinin, following the 'High Dose' protocol, is an important tool in adult valvular surgery to substantially reduce risks related to bleeding, reexplorations and donor blood transfusions.",
keywords = "adults, aprotinin, heart valves, surgery",
author = "P. Gerometta and C. Antona and A. Parolari and P. Fratto and F. Alamanni and R. Spirito and V. Arena and P. Biglioli",
year = "1995",
language = "Italian",
volume = "43",
pages = "47--54",
journal = "Minerva Cardioangiologica",
issn = "0026-4725",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "1-2",

}

TY - JOUR

T1 - STUDIO RETROSPETTIVO SULL'EFFICACIA DELL'APROTININA NELLA CHIRURGIA VALVOLARE DELL'ADULTO

AU - Gerometta, P.

AU - Antona, C.

AU - Parolari, A.

AU - Fratto, P.

AU - Alamanni, F.

AU - Spirito, R.

AU - Arena, V.

AU - Biglioli, P.

PY - 1995

Y1 - 1995

N2 - Aprotinin effects on postoperative bleeding, redo operations due to excessive bleeding and postoperative blood products use have been retrospectively evaluated on a population of 894 consecutive patients operated upon between 1987 and 1991 for valvular surgery. In this period, aprotinin has been routinely used following the 'High Dose' protocol starting from January 1990. To analyse results, all the patients considered (Group I) were divided into subgroups, following the heart valve operated upon, in 'mitral' patients (391 patients, 43.7%, Group II), 'aortic' patients (375 patients, 41,9%, Group III) and 'mitro-aortic' patients (128 patients, 14.3%, Group IV). Each of these Groups has been subsequently split depending on whether or not they received aprotinin (Subgroups IA, IIA, IIIA, IVA with aprotinin, subgroups IB, IIB, IIIB, IVB without aprotinin). Considering the whole population (Group I), aprotinin determined a significant reduction of post-operative bleeding (499 ± 634 ml Group IA versus 713 ± 572 Group IB, p = 0.000), redo operations for bleeding (15/410, 3.7% Group IA versus 45/484, 9.3% Group IB, p = 0.0000) and consequently the percentage of patients exposed to blood products transfusion (37/410, 9% Group IA versus 163/484, 54.3% Group IB p = 0.0000). When the other Groups (II, III and IV) were considered, aprotinin determined a significant reduction of postoperative bleeding and of donor blood transfusions, while redo operations for bleeding, although less in total number, were not significantly reduced. Moreover, aprotinin has been effective in reducing postoperative blood losses, redo-operation for bleeding and blood use independently of the kind of oxygenator used: bubble vs hollow fibers. We consider that intraoperative administration of aprotinin, following the 'High Dose' protocol, is an important tool in adult valvular surgery to substantially reduce risks related to bleeding, reexplorations and donor blood transfusions.

AB - Aprotinin effects on postoperative bleeding, redo operations due to excessive bleeding and postoperative blood products use have been retrospectively evaluated on a population of 894 consecutive patients operated upon between 1987 and 1991 for valvular surgery. In this period, aprotinin has been routinely used following the 'High Dose' protocol starting from January 1990. To analyse results, all the patients considered (Group I) were divided into subgroups, following the heart valve operated upon, in 'mitral' patients (391 patients, 43.7%, Group II), 'aortic' patients (375 patients, 41,9%, Group III) and 'mitro-aortic' patients (128 patients, 14.3%, Group IV). Each of these Groups has been subsequently split depending on whether or not they received aprotinin (Subgroups IA, IIA, IIIA, IVA with aprotinin, subgroups IB, IIB, IIIB, IVB without aprotinin). Considering the whole population (Group I), aprotinin determined a significant reduction of post-operative bleeding (499 ± 634 ml Group IA versus 713 ± 572 Group IB, p = 0.000), redo operations for bleeding (15/410, 3.7% Group IA versus 45/484, 9.3% Group IB, p = 0.0000) and consequently the percentage of patients exposed to blood products transfusion (37/410, 9% Group IA versus 163/484, 54.3% Group IB p = 0.0000). When the other Groups (II, III and IV) were considered, aprotinin determined a significant reduction of postoperative bleeding and of donor blood transfusions, while redo operations for bleeding, although less in total number, were not significantly reduced. Moreover, aprotinin has been effective in reducing postoperative blood losses, redo-operation for bleeding and blood use independently of the kind of oxygenator used: bubble vs hollow fibers. We consider that intraoperative administration of aprotinin, following the 'High Dose' protocol, is an important tool in adult valvular surgery to substantially reduce risks related to bleeding, reexplorations and donor blood transfusions.

KW - adults

KW - aprotinin

KW - heart valves, surgery

UR - http://www.scopus.com/inward/record.url?scp=0029032504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029032504&partnerID=8YFLogxK

M3 - Articolo

VL - 43

SP - 47

EP - 54

JO - Minerva Cardioangiologica

JF - Minerva Cardioangiologica

SN - 0026-4725

IS - 1-2

ER -